We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+35.24%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.54B
AUM Growth
+$917M
Cap. Flow
+$107M
Cap. Flow %
3.03%
Top 10 Hldgs %
51.42%
Holding
131
New
31
Increased
26
Reduced
8
Closed
26

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$88M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$70.6M
3
BPMC
Blueprint Medicines
BPMC
+$30.6M
4
AMRN
Amarin Corp
AMRN
+$30M
5
TDOC icon
Teladoc Health
TDOC
+$26.6M

Top Sells

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$105M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$71M
3
ARGX icon
argenx
ARGX
+$53.9M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$41M
5
XLRN
Acceleron Pharma
XLRN
+$39.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.08%
2 Miscellaneous 2.54%
3 Consumer Staples 0.8%
4 Financials 0.51%
5 Technology 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRCA icon
26
Verrica Pharmaceuticals
VRCA
$78.7M
$38.5M 1.09%
341,041
– –
VRAY
27
DELISTED
ViewRay, Inc.
VRAY
$35.5M 1%
4,805,650
+900,000
+23% +$6.94M
KDMN
28
DELISTED
Kadmon Holdings, Inc.
KDMN
$34.8M 0.98%
13,165,746
– –
CTMX icon
29
CytomX Therapeutics
CTMX
$586M
$34.1M 0.96%
3,173,923
+262,208
+9% +$3.88M
NEPT
30
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$28.4M 0.8%
6,351
– –
ALDX icon
31
Aldeyra Therapeutics
ALDX
$82.6M
$27.9M 0.79%
3,085,458
– –
DOVA
32
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$27.8M 0.78%
3,125,851
– –
TDOC icon
33
Teladoc Health
TDOC
$1.2B
$27.5M 0.78%
495,000
+435,000
+725% +$26.6M
CNCE
34
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$26.6M 0.75%
2,204,641
+330,862
+18% +$4.88M
NVRO
35
DELISTED
NEVRO CORP.
NVRO
$26.1M 0.74%
+416,949
New +$19.6M
ADMA icon
36
ADMA Biologics
ADMA
$1.93B
$24.7M 0.7%
6,521,102
– –
VAPO
37
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$24.5M 0.69%
155,789
+2,500
+2% +$359K
KOD icon
38
Kodiak Sciences
KOD
$2.07B
$20.5M 0.58%
3,135,199
– –
EHTH icon
39
eHealth
EHTH
$28.5M
$18.1M 0.51%
289,857
+234,836
+427% +$12.9M
FOMX
40
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$17.5M 0.49%
4,661,824
– –
AXNX
41
DELISTED
Axonics, Inc. Common Stock
AXNX
$16.4M 0.46%
685,756
-65,244
-9% -$1.18M
EIDX
42
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$16.1M 0.45%
686,992
+70
+0% +$1.12K
IRTC icon
43
iRhythm Holdings
IRTC
$3.69B
$15M 0.42%
+200,000
New +$17.1M
BHC icon
44
Bausch Health
BHC
$2.12B
$14.8M 0.42%
+600,000
New +$14.3M
ESTA icon
45
Establishment Labs
ESTA
$2.13B
$14.8M 0.42%
614,242
– –
AKBA icon
46
Akebia Therapeutics
AKBA
$250M
$14M 0.39%
1,703,440
– –
QURE icon
47
uniQure
QURE
$2.99B
$13.8M 0.39%
231,820
+11,113
+5% +$496K
RYTM icon
48
Rhythm Pharmaceuticals
RYTM
$6.66B
$13.8M 0.39%
502,970
-6,216
-1% -$179K
LITS
49
Lite Strategy Inc
LITS
$37.1M
$13.5M 0.38%
220,022
– –
MRKR icon
50
Marker Therapeutics
MRKR
$19.5M
$13.2M 0.37%
200,000
– –
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2019 Portfolio in Review

As of Q1 2019, Perceptive Advisors held 131 positions worth $3.54B, up 35% from $2.63B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors deployed $107M of net new capital in Q1 2019, opening 31 new positions and adding to 26 existing holdings. Its largest new stake was Array Biopharma Inc: 4,228,900 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $71M trimmed.

  • Perceptive Advisors's largest Q1 2019 buy was Array Biopharma Inc: 4,228,900 shares worth $103M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q1 2019, an estimated $70.6M increase.
  • Perceptive Advisors's biggest Q1 2019 reduction was Neurocrine Biosciences, cutting an estimated $71M.
  • Perceptive Advisors fully exited Solid Biosciences in Q1 2019, selling an estimated $105M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $3.54B portfolio in Q1 2019.
  • Perceptive Advisors opened 31 new positions and closed 26 in Q1 2019.
  • Perceptive Advisors's portfolio value rose 35% quarter-over-quarter to $3.54B.

Based on Perceptive Advisors's 13F filing for Q1 2019, filed 15 May 2019.